Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of IR103 HIV-1 Antigen plus Amplivax in IFA vs Remune HIV-1 Antigen in IFA in Antiretroviral-Naive HIV-1 Infected Subjects
2004-005050-31Phase 2Terminated
- Sponsor
- The Immune Response Corporation
- Start
- Feb 2007
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2 trial of IR103 HIV-1 antigen, Amplivax and hiv-1 immunogen in human immunodeficiency virus infection (HIV) (2 arms), sponsored by The Immune Response Corporation. Primary endpoints: Safety and Immunogenicity. Started Feb 2007; status: terminated.
02
Drugs
IR103 HIV-1 antigenAmplivaxhiv-1 immunogen
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2004-005050-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-005050-31.